Published in final edited form as:

J Neurol Neurosurg Psychiatry. 2018 November ; 89(11): 1174–1180. doi:10.1136/jnnp-2018-318215.

Serum anti gliadin antibodies in cerebellar ataxias: a systematic review and meta-analysis

Chi-Ying Lin¹, Min-Jung Wang², Winona Tse¹, Rachel Pinotti³, Armin Alaedini⁴, Peter H R Green⁴, and Sheng-Han Kuo⁵

¹Department of Neurology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA

²Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA

³Levy Library, Icahn School of Medicine at Mount Sinai, New York City, New York, USA

⁴Department of Medicine, College of Physicians and Surgeons, Columbia University, New York City, New York, USA

⁵Department of Neurology, College of Physicians and Surgeons, Columbia University, New York City, New York, USA

Abstract

Background—Gluten sensitivity refers to prominent immunological responses to gluten, usually in conjunction with elevated levels of serum anti gliadin antibody (AGA). The association between AGA and cerebellar ataxias has been inconsistently reported.

Methods—We performed a systematic literature search and a meta-analysis to study the weighted pooled OR of idiopathic cerebellar ataxia (IDCA) cases to controls or to hereditary ataxia (HA) for AGA seropositivity using fixed effect model.

Results—Eleven studies were included, with a total of 847 IDCA cases, 1654 controls and 445 HA cases. IDCA cases had fourfold higher odds than controls (OR 4.28, 95% CI 3.10 to 5.90) and twofold higher odds than HA cases (OR 2.23, 95% CI 1.45 to 3.44) of having AGA seropositivity. Sensitivity analysis excluding the most weighted study, which accounted for 69% of the total weight, still showed similar associations (IDCA vs controls, OR 3.18, 95% CI 1.79 to 5.67 and IDCA vs HA, OR 1.72, 95% CI 1.03 to 2.86, respectively). The subgroup analysis showed that,

Correspondence to Dr Sheng-Han Kuo, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10032 USA; sk3295@columbia.edu.

Contributors C-YL: study concept, data acquisition, analysis and interpretation, manuscript draft and revision; M-JW: conducting meta-analysis, data analysis and interpretation and revision of the manuscript; WT: data acquisition and interpretation and critical revision of the manuscript for important intellectual content; RP: guidance and oversight on search strategy design and execution, preparation of results for screening and study selection processes, critical revision of the Methods section of the manuscript; AA: study concept, analysis and interpretation, critical revision of the manuscript for important intellectual content; PHRG: study concept, analysis and interpretation, critical revision of the manuscript for important intellectual content; S-HK: study concept, data acquisition, analysis and interpretation, critical revision of the manuscript for important intellectual content and study supervision.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

when compared with controls, IDCA cases of both East Asian and Western countries had approximately threefold to fourfold higher odds to have AGA seropositivity (OR 3.41, 95% CI 1.67 to 6.97 and OR 4.53, 95% CI 3.16 to 6.49, respectively), suggesting the lack of ethnic heterogeneity. The odds of AGA seropositivity for HA cases was not significantly higher than controls (OR 1.41, 95% CI 0.82 to 2.44).

Conclusion—Our study indicates the association between AGA and IDCA, across different geographic regions.

INTRODUCTION

The differential diagnosis of cerebellar ataxia is broad, including hereditary and degenerative causes, and few disease-specific treatments are available. Immune-mediated cerebellar ataxias are characterised by serum or cerebrospinal fluid antibody positivity, mild or absence of the cerebellar atrophy on structural neuroimaging at the initial stage and the responsiveness to immunomodulatory therapy.¹² Established immune-mediated cerebellar ataxias are relatively rare, among which gluten ataxia has been reported to be the most common. Gluten ataxia refers to cerebellar ataxia associated with gluten sensitivity, a prominent immunological response to gluten intake, for which the human body produces abnormally high titres of serum antiglutin antibodies.³⁴ Gluten sensitivity is considered a gluten-related disorder separate from coeliac disease, which is characterised by the presence of antibodies to tissue transglutaminase 2 (TTG2) and inflammatory changes in the small intestine.⁵ Patients with gluten sensitivity lack these changes; however, might have evidence of alterations in intestinal permeability.⁶ The presence of antibodies to gliadin is considered to represent a form of gluten sensitivity.⁷ Patients with cerebellar ataxia with antiglutin antibodies could respond to gluten-free diet or immunoglobulin therapy,² representing a treatable form of cerebellar ataxia.

Antigluten antibodies are generated in response to gluten proteins existing in wheat, rye and barley, among which anti-gliadin antibody (AGA) is most studied in patients with cerebellar ataxia.⁸ AGA has been reported in 43% of otherwise idiopathic cerebellar ataxia (IDCA) cases; however, AGA is also found in up to 12% controls and in 13% hereditary ataxia (HA) cases.^{9,10} When comparing with controls, IDCA cases are thus more commonly reported to have AGA seropositivity.¹⁰ However, these results have been inconsistently replicated.^{3,11–14} Several factors such as ethnic backgrounds and different methodologies used for AGA detection have been postulated to explain the discrepancy between studies,¹² but there is no systematic review for these important questions. Therefore, we performed a meta-analysis to examine the association between AGA seropositivity and cerebellar ataxia and to investigate the factors accounting for the discrepancies between studies.

METHODS

Data sources and searches

The methodology used for the systematic review and meta-analysis followed the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (www.prisma-statement.org). C-YT and RP composed a comprehensive search

strategy using both subject headings and all relevant keywords, including antigliadin antibody, cerebellar ataxia and gluten. The search was executed in the MEDLINE, EMBASE and SCOPUS databases from their inception through 15 April 2017, with the goal of identifying all published material relevant to AGA in cerebellar ataxias. Google Scholar was also searched and the first 100 pages of search results were reviewed to identify additional relevant materials. All results from the databases as well as selected results from Google Scholar were uploaded to COVidence and the result set was de-duplicated. The detailed search strategy is provided in online supplementary file 1.

Study selection and quality assessment

Study selection was conducted independently by two independent reviewers (C-YL and S-HK) according to predetermined eligibility criteria. The eligibility criteria were designed to be relatively broad and inclusive, as studies related to cerebellar ataxias with serological testing for AGA were expected to be relatively uncommon. We thus included both case-control and cross-sectional studies with patients diagnosed with IDCA, HA and/or healthy controls who received AGA serological testing. The exclusion criteria were as follows: a single case report, review articles, lack of measurement of AGA and studies not written in English. The primary outcome of interest was the presence or absence of serum AGA. It is required that the IDCA cases of the recruited studies should have no other known causes of the cerebellar ataxias, including genetics.¹⁵ Age was not considered as a factor for study exclusion because the majority of the current published studies did not specify study subjects' individual demographics.

Studies from the search were initially screened on the basis of their titles and abstracts. Incongruent decisions (ie, one voted for 'yes' to include for the full-text review and the other voted for 'no') and controversial opinions (eg, one or both voted for 'maybe') between the two independent reviewers were then resolved by the third reviewer (WT). The studies identified based on the title and abstract screening were then included for full-text review. The full-text review was again performed by two independent reviewers (C-YL and S-HK) and any disagreement between the two reviewers was resolved by the third reviewer to reach the consensus for making the final decision of the inclusion for qualitative assessment. Newcastle-Ottawa Quality Assessment Scale Adapted for Cross-Sectional Studies¹⁶ was used for assessment of the study selection, comparability and outcome, and articles rated 7 stars or above on the scale¹⁶ were considered good quality and included for the meta-analysis.

Data extraction

The OR of each included study was calculated by a single reviewer (C-YL). Calculating the OR required the number of the patients and controls in the exposure (with AGA) and non-exposure groups (without AGA), respectively; therefore, if the original study used the percentage for the prevalence of AGA seropositivity, the percentage would be converted to the subject number. The decimal would be rounded up to an integer as the subject number. While all 11 studies measured both AGA IgA and IgG, only two studies specify in the results separately for the prevalence of AGA IgA and IgG,^{17,18} for which we chose OR of AGA IgG for pooling effect in the primary analysis because IgG typically stands for the

antibody indicative of long-standing immunity and could more reliably reflect the long-term gluten sensitivity. We did not have sufficient sample size to independently evaluate AGA IgA and cerebellar ataxia.

Data synthesis and statistical analysis

Our primary analysis is the pooled OR of IDCA cases to controls ($OR_{I/C}$) and secondary analysis is the pooled OR of IDCA cases to HA cases ($OR_{I/H}$). The rationale of performing secondary analysis is that HA could serve as a disease control against the possibility that the cerebellar damages caused by genetic and neurodegenerative factors might expose antigens leading to an antibody cross-reactivity with gliadin/TTG6, and also the possibility that the subclinical pre-existing cerebellar disease due to genetic and neurodegenerative factors may predispose the cerebellum to immunological damages. The pooled effects were presented as OR with 95% CIs, and the studies were weighted using the Mantel-Haenszel test for pooled OR. We quantified the statistical heterogeneity by calculating I^2 statistics (ie, the percentage of the total variation across the studies due to effect size heterogeneity) between studies. An I^2 value of 0% indicates no observed heterogeneity; 25% is low, 50% is moderate and 75% is high heterogeneity. The heterogeneity was considered significant if the heterogeneity p value was <0.05 . We used fixed effects model with the assumption that the study sample, method and effect sizes were not different across the included studies. We performed the meta-analyses using STATA V14. In addition, we further explored the geographic regions where the patients were recruited/studies were conducted since it would reflect information regarding ethnicity differences. We assessed publication bias by inspecting the shape of the funnel plot for the log OR against the log OR SE, and by performing the Egger test.

RESULTS

Our search identified 206 citations (figure 1). After removing duplicate records, 159 unique citations entered the process of title and abstract screening, of which 133 (83.6%) were excluded according to the exclusion criteria and additional duplicated articles not detected initially by COVIDENCE but later on by our review of citations. Our independent raters had good initial agreement on inclusion of full-text review ($\kappa=0.65$, $SE=0.06$, $p=0.54-0.76$). After resolving initial disagreements, 11/26 (42.3%) studies⁹¹¹⁻¹⁴¹⁷⁻²² were considered eligible (figure 1), representing 6.9% of the total search (11/159). The reasons for excluding 15/26 articles⁸²³⁻³⁶ in the order of high to low percentage are as follows: studies only on IDCA cases without HA cases or controls ($n=6$, 40%),⁸²³²⁶²⁷³⁰³² studies on cases of ataxia with or without coeliac disease instead of ataxia cases versus controls ($n=3$, 20%),³¹³³³⁴ studies that defined IDCA distinctively from the general consensus (ie, non-genetic ataxias caused by acquired conditions and sporadic neurodegenerative disorders)¹⁵ ($n=2$, 13.3%),¹⁵³⁴ a study that only tested for anti-deamidated gliadin peptide (DGP) antibody without testing for AGA ($n=1$, 6.7%),²⁵ a study that only tested for anti TTG2 antibody without testing for AGA ($n=1$, 6.7%),²⁹ a study that did not include IDCA cases ($n=1$, 6.7%)²⁴ and a duplicated study with same patient groups but under different titles ($n=1$, 6.7%).³⁶ These 11 studies included in the meta-analysis were all rated as 7 stars or above on Newcastle-Ottawa Quality Assessment Scale Adapted for Cross-Sectional Studies and thus

included for meta-analysis. A total of 847 patients with IDCA, 445 HA cases and 1654 controls were included.

Our review showed that the percentage of AGA seropositivity in IDCA, HA and controls greatly vary across the studies (table 1). Our primary analysis showed that IDCA cases have fourfold higher odds than controls of being found as seropositive for AGA (overall $OR_{I/C}=4.28$, 95% CI 3.10 to 5.90, $p<0.001$, seven studies⁹¹²⁻¹⁴¹⁸⁻²⁰; $I^2=38.5\%$, $p=0.135$) (figure 2A). We also found that IDCA cases have twofold higher odds than HA cases of being found as seropositive for AGA ($OR_{I/H}=2.23$, 95% CI 1.45 to 3.44, nine studies⁹¹¹¹³¹⁴¹⁷⁻²⁰; $I^2=32.4\%$, $p=0.159$) after excluding one study²¹ of infinite OR due to no AGA seropositivity in patients with HA (figure 2B). Visual examination of the funnel plot of the $OR_{I/C}$ (see online supplementary figure 1A) and $OR_{I/H}$ (see online supplementary figure 1B) showed no deviation of the funnel shape with the studies evenly spread on both sides, which was further supported by the Egger regression test for funnel plot asymmetry ($p=0.95$ for $OR_{I/C}$, $p=0.16$ for $OR_{I/H}$, $p=0.16$ for $OR_{H/C}$). These indicate these studies have no significant publication bias.

For the six studies that included HA cases and controls,⁹¹³¹⁴¹⁸⁻²⁰ the odds of AGA seropositivity for HA cases was not significantly higher than controls ($OR\ 1.41$, 95% CI 0.82 to 2.44, $p=0.215$).

We found that the pooled $OR_{I/C}$ was primarily driven by one particular study with a large sample size,⁹ which contributed to 69% of the total weight. Thus, we performed further sensitivity analysis to exclude this study and the odds of AGA seropositivity was still threefold higher in IDCA cases than controls ($OR_{I/C}=3.18$, 95% CI 1.79 to 5.67, $p<0.001$, six studies¹²⁻¹⁴¹⁸⁻²⁰; $I^2=39.8\%$, $p=0.140$). Similarly, IDCA cases still had close to twofold higher odds of being found as seropositive for AGA than HA cases after excluding the most weighted study ($OR_{I/H}=1.72$, 95% CI 1.03 to 2.86, $p=0.04$, eight studies¹¹¹³¹⁴¹⁷⁻²⁰²²; $I^2=14.4\%$, $p=0.317$).

We next investigated the factors that could influence the association between AGA and IDCA cases. We first conducted the geographic region-specific subgroup analysis. The pooled $OR_{I/C}$ for the East Asian subgroup (three studies from Taiwan,¹³ Japan¹² and China¹⁸) was 3.41 (95% CI 1.67 to 6.97, $p=0.001$; $I^2=73.2\%$, $p=0.024$) and the pooled $OR_{I/C}$ for the rest of the studies (four studies from the UK,⁹²⁰ Germany¹⁹ and Canada¹⁴) was 4.53 (95% CI 3.16 to 6.49, $p<0.001$; $I^2=0.0\%$, $p=0.509$) (figure 3A). We further compared odds of AGA between IDCA cases and HA cases. Two Asian studies¹³¹⁸ had a pooled $OR_{I/H}$ 3.08 (95% CI 1.41 to 6.72, $p=0.005$; $I^2=49.4\%$, $p=0.160$), whereas seven non-Asian studies⁹¹¹¹⁴¹⁷¹⁹²⁰²² had a slightly lower pooled $OR_{I/H}$ of 1.94 (95% CI 1.15 to 3.26, $p=0.013$; $I^2=32.7\%$, $p=0.178$) (figure 3B). In summary, the association between AGA seropositivity and IDCA cases could be similarly observed across different geographic regions.

DISCUSSION

Significantly increased rates of seropositivity for serum antibody to gluten proteins were previously found in some patients with IDCA in the absence of coeliac disease, some of whom were also found to have a clinical response to a gluten-free diet.¹⁰³⁷ Therefore, cerebellar ataxia has been suggested as one of the presentations of gluten sensitivity.³⁰ Since gluten ataxia is a relatively rare disorder, meta-analysis presents as a useful tool to study the prevalence of such disorder across different geographic regions, and this method could also be applied to other immune-mediated cerebellar ataxias. Our meta-analysis of available studies supports the notion that AGA seropositivity is associated with cerebellar ataxias. In our analysis, the main pooled $OR_{I/C}$ and $OR_{I/H}$ are driven by the study conducted by Hadjivassiliou *et al* based on its large sample size.⁹ After excluding this study that accounts for nearly 70% of the total weight, the pooled $OR_{I/C}$ and $OR_{I/H}$ in the rest of the included studies were similar, which further corroborates the association between AGA seropositivity and cerebellar ataxias. To our knowledge, this is the first systematic review and meta-analysis exploring the association between gluten sensitivity and cerebellar ataxia. The overall odds of having cerebellar ataxias are over fourfold higher in patients with gluten sensitivity.

There are significant differences in the prevalence of cerebellar ataxic disorders between Western and Asian populations, such as multiple sclerosis (neuroinflammatory causes), and multiple system atrophy-cerebellar type (degenerative causes).³⁸³⁹ Interestingly, we found that the association between AGA seropositivity and cerebellar ataxias is similar across different geographic regions in our meta-analysis. On the other hand, coeliac disease is much rare in most Asian countries such as Japan,⁴⁰ making a clear distinction between gluten ataxia and coeliac disease. None of the studies indicated the coexistence of coeliac disease in cases with cerebellar ataxia associated with gluten sensitivity, which deserve further investigation.

One of the major confounding factors among the included studies is the different cut-off values, and different manufacturers (table 1) using different antigens and standards for AGA seropositivity, which might account for some inconsistency between the absolute prevalence of AGA in different studies. Thus, the systematic review of our study also highlights the importance of unifying the analytic methods to detect the presence of AGA and to define the titre threshold for AGA 'seropositivity'. A uniform protocol is required to adequately compare and to further define the disease prevalence, the response rate of gluten-free diet and/or immunomodulatory therapy in patients with the aforementioned predefined threshold for AGA seropositivity.

Anti-DGP antibody is considered a sensitive and specific marker for coeliac disease and follows closely with the antibodies to TTG2.⁵ AGA is considered neither sensitive nor specific for coeliac disease⁴¹ while the presence of anti-TTG2 or anti-DGP seropositivity indicates coeliac disease,⁵ separating from (non-coeliac) gluten sensitivity. In other words, all/most patients with coeliac disease have AGA as well as anti-TTG/DGP seropositivity, and most AGA seropositive patients without anti-TTG/DGP seropositivity are considered (non-coeliac) gluten sensitive.⁵⁴¹ While AGA is the most commonly studied antibody to be

associated with cerebellar ataxia, the antitransglutaminase 6 (TG6) antibody has been proposed to be more specific to the gluten sensitivity associated with cerebellar ataxia²²—this is especially true given that AGA seropositivity could be found in about 10% of healthy subjects, AGA thus may sometimes be considered as an epiphenomenon and the search for more specific antibody as the disease marker is needed. However, there are no widely standardised and commercially available methods to detect anti-TG6 antibodies. There is only one study in our meta-analysis that measured anti-TG6, which yields the OR_{IC} of 9.31.²⁹ Further systematic system of anti-TG6 and gluten ataxia is needed.

The limitation of this systematic review and meta-analysis is that all studies included were cross-sectional and the sample size is relatively small; however, this does not mean the finding is not applicable to the population level across different geographic regions. At the individual patient level, it is still debatable whether AGA is pathognomonic of immune-mediated cerebellar ataxias given a significant portion of HA cases and controls also have AGA seropositivity. The prevalence of AGA seropositivity in healthy subjects carries the implicit warning that finding AGA seropositivity in an ataxic patient should not necessarily result in diagnostic closure. In addition, not every patient with ataxia with AGA seropositivity responds to gluten-free diet or intravenous immunoglobulin; therefore, other causes of ataxia might also sometimes be considered. Therefore, the recognition of gluten sensitivity in patients with ataxia may be highly important to initiate gluten-free diet. Future research should focus on standardised methods with a consensus of cut-off values of AGA seropositivity, which will serve as a starting point to further clearly define gluten ataxia as a disease entity. In addition, identifying the disease-specific antibodies such as anti-TG6 will also be important for elucidating the immune-mediated causes of the cerebellar ataxias.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding S-HK has received funding from the National Institutes of Health: NINDS #K08 NS083738 (principal investigator), and the Louis V Gerstner Jr. Scholar Award, Parkinson's Foundation and International Essential Tremor Foundation.

REFERENCES

1. Mitoma H, Adhikari K, Aeschlimann D, et al. Consensus paper: neuroimmune mechanisms of cerebellar ataxias. *Cerebellum* 2016;15:213–32. [PubMed: 25823827]
2. Mitoma H, Hadjivassiliou M, Honnorat J. Guidelines for treatment of immune-mediated cerebellar ataxias. *Cerebellum Ataxias* 2015;2:14. [PubMed: 26561527]
3. Bushara K, Hallett M. Prevalence of antigliadin antibodies in ataxia patients. *Neurology* 2004;62:1237.2–8.
4. Marsh MN. The natural history of gluten sensitivity: defining, refining and re-defining. *QJM* 1995;88:9–13. [PubMed: 7894995]
5. Green PH, Cellier C. Celiac disease. *N Engl J Med* 2007;357:1731–43. [PubMed: 17960014]
6. Uhde M, Ajamian M, Caio G, et al. Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease. *Gut* 2016;65:1930–7. [PubMed: 27459152]

7. Catassi C, Bai JC, Bonaz B, et al. Non-celiac gluten sensitivity: the new frontier of gluten related disorders. *Nutrients* 2013;5:3839–53. [PubMed: 24077239]
8. Bürk K, Bösch S, Müller CA, et al. Sporadic cerebellar ataxia associated with gluten sensitivity. *Brain* 2001;124:1013–9. [PubMed: 11335703]
9. Hadjivassiliou M, Grünewald R, Sharrack B, et al. Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. *Brain* 2003;126:685–91. [PubMed: 12566288]
10. Hadjivassiliou M, Sanders DD, Aeschlimann DP. Gluten-related disorders: gluten ataxia. *Dig Dis* 2015;33:264–8. [PubMed: 25925933]
11. Bushara KO, Goebel SU, Shill H, et al. Gluten sensitivity in sporadic and hereditary cerebellar ataxia. *Ann Neurol* 2001;49:540–3. [PubMed: 11310636]
12. Ihara M, Makino F, Sawada H, et al. Gluten sensitivity in Japanese patients with adult-onset cerebellar ataxia. *Intern Med* 2006;45:135–40. [PubMed: 16508226]
13. Liu CS, Soong BW, Lee YC, et al. Gluten sensitivity: associated sporadic cerebellar ataxia in Taiwan. *Acta Neurol Taiwan* 2010;19:263–9. [PubMed: 21210327]
14. Wong D, Dwinell M, Schulzer M, et al. Ataxia and the role of anti gliadin antibodies. *Can J Neurol Sci* 2007;34:193–6. [PubMed: 17598597]
15. Fogel BL, Perlman S. An approach to the patient with late-onset cerebellar ataxia. *Nat Clin Pract Neurol* 2006;2:629–35. [PubMed: 17057750]
16. Modesti PA, Reboldi G, Cappuccio FP, et al. Panethnic differences in blood pressure in europe: a systematic review and meta-analysis. *PLoS One* 2016;11:e0147601. [PubMed: 26808317]
17. Abele M, Bürk K, Schöls L, et al. The aetiology of sporadic adult-onset ataxia. *Brain* 2002;125:961–8. [PubMed: 11960886]
18. Guan WJ, Liu XJ, Tang BS, et al. Gluten ataxia of sporadic and hereditary cerebellar ataxia in patients from mainland China. *Neurol India* 2013;61:226–30. [PubMed: 23860139]
19. Abele M, Schöls L, Schwartz S, et al. Prevalence of anti gliadin antibodies in ataxia patients. *Neurology* 2003;60:1674–5. [PubMed: 12771263]
20. Lock RJ, Tengah DP, Williams AJ, et al. Cerebellar ataxia, peripheral neuropathy, "gluten sensitivity" and anti-neuronal autoantibodies. *Clin Lab* 2006;52:589–92. [PubMed: 17175889]
21. Pellecchia MT, Scala R, Filla A, et al. Idiopathic cerebellar ataxia associated with celiac disease: lack of distinctive neurological features. *J Neurol Neurosurg Psychiatry* 1999;66:32–5. [PubMed: 9886447]
22. Sivera R, Martín N, Boscá I, et al. Autoimmunity as a prognostic factor in sporadic adult onset cerebellar ataxia. *J Neurol* 2012;259:851–4. [PubMed: 21984193]
23. Hamidian Y, Togha M, Nafisi S, et al. Anti gliadin antibody in sporadic adult ataxia. *Iran J Neurol* 2012;11:16–20. [PubMed: 24250853]
24. Almaguer-Mederos LE, Almira YR, Góngora EM, et al. Anti gliadin antibodies in Cuban patients with spinocerebellar ataxia type 2. *J Neurol Neurosurg Psychiatry* 2008;79:315–7. [PubMed: 17951282]
25. Nanri K, Mitoma H, Ihara M, et al. Gluten ataxia in Japan. *Cerebellum* 2014;13:623–7. [PubMed: 24997752]
26. Nanri K, Okuma M, Sato S, et al. Prevalence of autoantibodies and the efficacy of immunotherapy for autoimmune cerebellar ataxia. *Intern Med* 2016;55:449–54. [PubMed: 26935362]
27. Combarros O, Infante J, López-Hoyos M, et al. Celiac disease and idiopathic cerebellar ataxia. *Neurology* 2000;54:2346.
28. Fancellu R, Pareyson D, Corsini E, et al. Immunological reactivity against neuronal and non-neuronal antigens in sporadic adult-onset cerebellar ataxia. *Eur Neurol* 2009;62:356–61. [PubMed: 19786780]
29. Hadjivassiliou M, Aeschlimann P, Sanders DS, et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. *Neurology* 2013;80:1740–5. [PubMed: 23576621]
30. Hadjivassiliou M, Gibson A, Davies-Jones GA, et al. Does cryptic gluten sensitivity play a part in neurological illness? *Lancet* 1996;347:369–71. [PubMed: 8598704]
31. Hadjivassiliou M, Rao DG, Grinewald RA, et al. Neurological dysfunction in coeliac disease and non-coeliac gluten sensitivity. *Am J Gastroenterol* 2016;111:561–7. [PubMed: 26832652]

32. Rashtak S, Rashtak S, Snyder MR, et al. Serology of celiac disease in gluten-sensitive ataxia or neuropathy: role of deamidated gliadin antibody. *J Neuroimmunol* 2011;230:130–4. [PubMed: 21056914]
33. McKeon A, Lennon VA, Pittock SJ, et al. The neurologic significance of celiac disease biomarkers. *Neurology* 2014;83:1789–96. [PubMed: 25261501]
34. Luostarinen L, Pirttilä T, Collin P. Coeliac disease presenting with neurological disorders. *Eur Neurol* 1999;42:132–5. [PubMed: 10529537]
35. Luostarinen LK, Collin PO, Peräaho MJ, et al. Coeliac disease in patients with cerebellar ataxia of unknown origin. *Ann Med* 2001;33:445–9. [PubMed: 11585106]
36. Lock RJ, Pengiran Tengah DS, Unsworth DJ, et al. Ataxia, peripheral neuropathy, and anti-gliadin antibody. Guilt by association? *J Neurol Neurosurg Psychiatry* 2005;76:1601–3. [PubMed: 16227563]
37. Hadjivassiliou M, Grünewald RA, Chattopadhyay AK, et al. Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. *Lancet* 1998;352:1582–5. [PubMed: 9843103]
38. Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. *Lancet Neurol* 2013;12:264–74. [PubMed: 23391524]
39. Yabe I, Soma H, Takei A, et al. MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA. *J Neurol Sci* 2006;249:115–21. [PubMed: 16828805]
40. Cummins AG, Roberts-Thomson IC. Prevalence of celiac disease in the Asia-Pacific region. *J Gastroenterol Hepatol* 2009;24:1347–51. [PubMed: 19702902]
41. Infantino M, Manfredi M, Meacci F, et al. Diagnostic accuracy of anti-gliadin antibodies in Non Celiac Gluten Sensitivity (NCGS) patients: A dual statistical approach. *Clin Chim Acta* 2015;451:135–41. [PubMed: 26404177]

Figure 1.

Study selection flow diagram. ^aMEDLINE and Embase were searched via Ovid. Scopus was searched via [Scopus.com](https://www.scopus.com). ^bHand search of citation lists from Google Scholar, selected studies and investigators further identified five additional published articles for review. Abstracts marked as yes or maybe on COVIDENCE by one or two reviewers were included in the full-text review. Different opinions between the two reviewers (C-YL and S-HK) in screening and eligibility were resolved by discussion and adjudication by a third, independent reviewer (WT). AGA, antigliadin antibody; CD, coeliac disease; DGP, deamidated gliadin peptide; TTG, tissue transglutaminase.

Figure 2.

Pooled OR for anti-gliadin antibody seropositivity in idiopathic cerebellar ataxias vs controls (A) and idiopathic cerebellar ataxias vs hereditary ataxias (B) are represented by the diamonds. The grey solid squares indicate the OR of the individual study result. The size of the squares refers to the weight that each study contributes to the overall meta-analysis. The 95% CI for the individual and the pooled OR is specified.

Figure 3.

Region-specific pooled OR for anti-glialadin antibody seropositivity in idiopathic cerebellar ataxias vs controls (A) and idiopathic cerebellar ataxias vs hereditary ataxias (B) are represented by the diamonds. The grey solid squares indicate the OR in individual study result. The size of the squares refers to the weight that each study contributes to the overall meta-analysis. The 95% CI for the individual and the pooled OR is specified.

Table 1

Characteristics of included studies

Author (year)	Type of study	Country	IDCA (n)	HA (n)	Healthy control (n)	Other diseases (n)	AGA seropositivity (n/percentage)	ELISA kit
Abele <i>et al</i> (2002) ¹⁷	Cross-sectional	Germany	65	15	–	MSA: 32	IDCA (10/15%); HA (1/7%)	Pharmacia, Erlangen, Germany
Abele <i>et al</i> (2003) ¹⁹	Cross-sectional	Germany	32	63	73	–	IDCA (4/13%); HA (6/10%); control (4/6%)	UniCap Gliadin IgG/IgA ImmunoCAP; Pharmacia Diagnostics, Germany
Bushara <i>et al</i> (2001) ¹¹	Cross-sectional	USA	26	24	–	–	IDCA (7/27%); HA (9/38%)	SCIMEDX, Denville, New Jersey, USA
Guan <i>et al</i> (2013) ¹⁸	Cross-sectional	China	100	25	51	–	IDCA (24/24%); HA (4/16%); control (8/16%)	Cusabio Biotech, Newark, Delaware, USA
Hadjivassiliou <i>et al</i> (2003) ⁹	Cross-sectional	UK	132*	59	1200	MSA-C: 33	IDCA (54/41%); HA (8/14%); control (149/12%)	Cogent Diagnostics, Edinburgh, UK
Ihara <i>et al</i> (2006) ¹²	Cross-sectional	Japan	14	–	47	PD: 9 ALS: 18	IDCA (3/21%); HA (2/14%); control (1/2%)	IMTEC Immundiagnostika GmbH, Berlin, Germany
Liu <i>et al</i> (2010) ¹³	Cross-sectional	Taiwan	361	207	194	–	IDCA (33/9%); HA (3/1%); control (2/1%)	IBL-Hamburg GmbH, Germany
Lock <i>et al</i> (2006) ²⁰	Cross-sectional	UK	20	7	30	Idiopathic peripheral neuropathy: 32	IDCA (8/40%); HA (3/43%); control (5/17%)	Orgentec Diagnostika, Mainz, Germany
Pellecchia <i>et al</i> (1999) ²¹	Cross-sectional	Italy	24	23	–	–	IDCA (3/13%); HA (0/0%)	Alfa-Gliatest, Eurospital, Trieste, Italy
Sivera <i>et al</i> (2012) ²²	Cross-sectional	Spain	44	43	–	Paraneoplastic cerebellar ataxia: 6	IDCA (6/14%); HA (3/7%)	Not described
Wong <i>et al</i> (2007) ¹⁴	Cross-sectional	Canada	29	18	59	MSA-C: 9	IDCA (2/7%); HA (1/6%); control (3/5%)	

* Additional 44 patients with IDCA from the other research group in London was recruited for AGA testing in addition to the original 132 patients with IDCA. These 44 are not included for meta-analysis because there was no HA and controls recruited at the same time.

AGA (+), positive anti gliadin antibody; ALS, amyotrophic lateral sclerosis; EIA, enzyme immune-assay; HA, hereditary ataxia; IDCA, idiopathic, sporadic ataxia; MSA, multiple system atrophy; MSA-C, multiple system atrophy cerebellar type; PD, Parkinson's disease.